Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Deferred Revenue (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Current Deferred Revenue data on record, last reported at $43.2 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 5.29% year-over-year to $43.2 million; the TTM value through Dec 2025 reached $43.2 million, down 5.29%, while the annual FY2025 figure was $43.2 million, 5.29% down from the prior year.
  • Current Deferred Revenue reached $43.2 million in Q4 2025 per FHTX's latest filing, down from $65.3 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $337.8 million in Q4 2021 and bottomed at $1.9 million in Q2 2021.
  • Average Current Deferred Revenue over 5 years is $64.2 million, with a median of $33.4 million recorded in 2023.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 16589.72% in 2021, then plummeted 90.28% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $337.8 million in 2021, then tumbled by 90.28% to $32.8 million in 2022, then rose by 5.27% to $34.6 million in 2023, then skyrocketed by 32.0% to $45.6 million in 2024, then fell by 5.29% to $43.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $43.2 million in Q4 2025, $65.3 million in Q3 2025, and $59.7 million in Q2 2025.